Ketamine alters the neurogenesis of rat cortical neural stem progenitor cells*
Chaoxuan Dong, MD, PhD; Cynthia R. Rovnaghi, MSc; K. J. S. Anand, MBBS, DPhil ketamine induced neuronal apoptosis in the developing brain (3) (4) (5) (6) (7) (8) (9) . Neural stem progenitor cells (NSPCs), as precursors of mature neurons and glia, play a critical role in normal brain development and have different biological characteristics from differentiated neurons and glia. For example, physiological apoptosis in NSPCs and neurons is morphologically indistinguishable, but its underlying mechanisms appear to be different (10) . To further evaluate the neurotoxic effects of ketamine on brain development, we explored the effects of ketamine on NSPCs from the rat fetal cortex.
Neurogenesis from NSPCs includes two processes: proliferation and differentiation. Activation of glutamate receptors can change the proliferation of neural stem cells or neural progenitor cells (NPCs), although the detailed mechanisms remain unclear (11) (12) (13) (14) (15) (16) (17) (18) (19) . Some studies reported that NMDAR activation increases the proliferation of NPCs (11, (14) (15) (16) (17) (18) , whereas other studies reported that NMDA reduces proliferation and inhibits neurosphere formation (12, 13, 19) .
NSPCs have the capacity of differentiating into neurons, astrocytes, and oligodendrocytes. Any factor interfering with neuronal differentiation may result in abnormalities in neuronal number, migration, synaptogenesis, and plasticity, thus altering structures in the developing brain. Repression of the calcium signaling mediated by glutamate receptors was associated with increased neuronal differentiation in human NPCs (20, 21) . NMDARs, as ligand-gated calcium channels, are involved in regulating neuronal differentiation of NSPCs (22, 23) , although it remains unclear if NMDAR activation promotes or inhibits the neuronal differentiation of NSPCs. In this study, we assessed the dose-and time-dependent effects of ketamine on proliferation and neuronal differentiation of cultured NSPCs isolated from the rat fetal cortex.
MATERIALS AND METHODS
Animals. All animal-use procedures were approved by the Institutional Animal Care and Use Committee of the University of Tennessee Health Science Center. Timed-pregnant Sprague-Dawley rats (Charles River) were housed at 24°C on a 12-hr:12-hr light:dark cycle with free access to food and water.
NSPCs Isolation and Cultures. NSPCs isolation procedures were completed as reported previously (24) . Briefly, the neocortex from embryonic day 17 rats was dissected, collected, and cut into small pieces for digestion in Accutase (Sigma, St. Louis, MO) at 37ºC; dissociated cells were rinsed and centrifuged at 120 × g for 5 min. Cell pellets were gently resuspended in proliferation medium Dulbecco's modified eagle medium: nutrient mixture F12 (Invitrogen/Gibco, Grand Island, NY) containing 20 ng/mL each of epidermal growth factor and basic fibroblast growth factor. Sieved cell suspensions were mixed with Percoll centrifugation medium, centrifuged at 21,000 × g for 30 min, achieving separation into two cellular layers. Cells from the lower layer (NSPCs) were rinsed and suspended in proliferation medium (Sigma). Isolated cells were seeded on poly-L-lysine precoated cell culture dishes, plates, or glass coverslips at a density appropriate for the surface area. Seeded cells were cultured in 5% CO 2 , 100% humidity at 37ºC. In each dish, half of the culture medium was replaced every 3 days. Adherent cells were passaged using Accutase. Cultures at passage 1 or 2 were used for all in vitro experiments.
Cell Treatments. In the dose-dependent assays, cultures were exposed to ketamine (Ketaset Pfizer, Fort Dodge, IA) at the following concentrations: 0 as control, 1, 10, 20, 50, and 100 µM for 24 hrs. In time-course assays, cultures were exposed to 10 µM of ketamine for different durations: 0 as control, ½, 1, 2, 4, 6, 8, 10, 12, 18, 24, and 48 hrs. In the proliferation assays, cultures were exposed to 5-bromo-2'-deoxyuridine (BrdU, 10 µM) for 24 hrs. In the differentiation tests, culture media were replaced with a differentiation medium containing 1% fetal bovine serum after different ketamine treatments. After allowing a 3-wk differentiation phase, cultures were fixed for immunostaining.
Immunofluorescent Staining. Treated cells were fixed in 4% paraformaldehyde, and rehydrated in phosphate buffered saline. Cells were incubated in blocking solution (5% normal goat serum in phosphate buffered saline) at room temperature. Cells were incubated overnight with primary antibodies (Table 1) at 4°C, then washed in phosphate buffered saline containing 0.1% Tween 20, followed by incubation with diluted Alexa Fluor (Invitrogen) secondary antibodies (Table 1) for 1 hr at room temperature. For nuclear staining, cells were incubated with 1 µg/mL 4′ 6-diamidino-2-phenylindole for 10 mins at room temperature. Finally, the cells were washed with phosphate buffered saline and mounted on glass slides using aqueous mounting media. Negative controls were the cells incubated without any primary antibody.
Cell-Death Assays. We utilized activated caspase-3 staining to detect apoptotic cells in the ketamine-treated NSPCs. Ketamine-exposed cultures were fixed and stained with active caspase-3 antibody and DAPI as described above. Caspase-3 + and DAPI + cells were quantified. The percentage of caspase-3 + cells in the total DAPI + cells represents the rate of apoptosis in NSPCs. Assays of lactate dehydrogenase (LDH) were performed (CytoTox 96 Non-Radioactive Cytotoxicity Assay Kit, ProMega, Madison, WI) to assess any necrotic changes (cell damage or lysis) in the NSPCs exposed to ketamine. All experimental procedures were performed based on manufacturer's protocols. Absorbance values were recorded at 490 nm.
Proliferation Assays. BrdU, a thymidine analogue, can be incorporated into newly synthesized DNA in the S phase of the cell cycle. Ki67, an endogenous marker, is expressed in the nucleus during all phases of the cell cycle. Thus, BrdU staining identifies newly generated cells, whereas Ki67 staining represents all proliferating cells. To detect the direct effects of BrdU on the proliferation of NSPCs, we added 10 µM of BrdU to the culture media for 0-48 hrs of exposure. Exposure to 10 µM BrdU for up to 24 hrs did not induce cell death in NSPCs; this was also reported by others (25, 26) . Treated cells were stained with BrdU, Ki67 antibodies, and DAPI based on the protocols described previously. The numbers of BrdU + , Ki67 + , and DAPI + cells were counted. The percentages of BrdU + in DAPI + cells, Ki67 + in DAPI + cells, and BrdU + in Ki67 + cells were calculated to represent the rates of newly generated cells, all proliferating cells, and newly generated cells among the proliferating cells, respectively.
Neuronal-Differentiation Assays. Cultures were exposed to different concentrations of ketamine (0-100 µM) in the differentiation medium (1% fetal bovine serum without basic fibroblast growth factor or epidermal growth factor) for 24 hrs, or to 10-µM ketamine for different durations (0-48 hrs). Following these treatments, culture media containing ketamine were removed and replaced with fresh differentiation media. Culture media were changed every 3 days. After 3 wks, cells were fixed and stained using Tuj-1 antibody and DAPI based on the protocols described above. The percentage of Tuj-1 + cells in DAPI + cells represented the rate of neuronal differentiation of NSPCs.
Image Capture and Cell Counting. A protocol-naive person collected the images from the coded samples to minimize potential observer bias. From each sample, ten visual fields at the magnification of 200× were randomly selected for image capture. All images were captured using an Olympus BX60 fluorescence microscope equipped with a Hamamatsu C4742-95 camera, using the Hamamatsu Imaging Software (HCImage 2.1 Live Version, Hamamatsu Photonics, Hamamatsu, Japan). Cells in each visual field were counted in a blinded manner. The total number of cells was based on the DAPI + cells. The percentage of a cell type per image field formed the data set (n=10) in each BrdU, bromo-deoxyuridine; GFAP, glial fibrillary acidic protein; IgG, immunoglobulin; NMDA, N-methyl-D-aspartate receptor.
Figure 1.
The isolation and identification of neural stem progenitor cells (NSPCs) from the fetal brain. A-C, rat fetal brain sections were immunostained using anti-Nestin (red), anti-Musashi-1 (red), anti-Musashi-1 (red), and 4′ 6-diamidino-2-phenylindole (DAPI) (blue); D-F, in vitro cultured NSPCs; D-E, adherent monolayer NSPC cultures at days 2-4 in vitro; F, NSPC neurospheres in a noncoated culture dish; G-I, the expression of Nestin, Tuj-1, and Musashi-1 in cultured NSPCs (confocal microscopy); G-H, Nestin (red) and Tuj-1 (green); I, Musashi-1 (red); J-L, the proliferative potency of NSPCs; J, bromo-deoxyuridine (BrdU) (green); K, Ki67 (red); (L), a merged picture of (J, K), and DAPI (blue); M-O, differentiation potency of NSPCs; M, Tuj-1 (red), a marker for newborn neurons; N, glial fibrillary acidic protein (GFAP) (green), a marker for astrocytes; O, a merged picture of (M, N) and DAPI (blue). (Scale bars = 50 µm.)
The expression of N-methyl-D-aspartate receptor (NMDA) receptors in cultured neural stem progenitor cells (NSPCs) from rat fetal cortex. A-C, the expression of NMDA-receptor subunit 1(NR1) in the rat fetal brain, NR1 (green) and 4′ 6-diamidino-2-phenylindole (DAPI) (blue). A, cortical plate (400× magnification); (B) , entire neocortex (100× magnification); (C), ventricular and subventricular zones (400× magnification). D and E, the expression of NR1 (green) in cultured NSPCs; (E) is a magnified picture of the inset of (D). F and G, the expression of NR2A and NR2B in cultured NSPCs. F, NR2A (green) and DAPI (blue); (G) NR2B (green) and DAPI (blue). (Scale bars = 50 µm.) independent experiment. All studies were repeated in three independent experiments.
Statistical Analyses. Statistical analyses were performed using Excel 2007 (Microsoft Corporation, Redmond, WA) and GraphPad InStat3 (GraphPad Software Inc., San Diego, CA). Independent samples of cultured NSPCs were used for observations made at each of the time points or drug concentrations used in our experiments. We used the Kolmogorov-Smirnov test for normal distribution and Levene's test for homogeneity before performing a one-way analysis of variance (ANOVA) on each data set. If ANOVA was significant, post hoc t tests were performed at each time point to investigate any differences between the parallel control and ketamine groups, followed by the Bonferroni correction for multiple comparisons. In the case of non-normal distribution, nonparametric tests were used (Kruskal-Wallis ANOVA and post hoc Mann-Whitney U tests). Statistical significance was set up at p<.05. All data were expressed as the mean ± standard error.
RESULTS
Isolation and Identification of NSPC Cultures. Two characteristic markers (Nestin and Musashi-1) were used to identify NSPCs in the fetal cortex ( Fig. 1A-C) , consistent with the wellknown cellular composition of fetal rat brains. When NSPCs were isolated, plated in precoated culture dishes, they grew to an adherent monolayer by 4 days in vitro (DIV 4) ( Fig. 1D-E) . When seeded in a noncoated culture dish, NSPCs grew into neurospheres by DIV4-5 ( Fig. 1F ). Tuj-1, Nestin, and Musashi-1 were employed to identify the cultures as NSPCs. All stained cells were Nestin + (Fig. 1G-H) and Musashi-1 + (Fig. 1I) . A few cells with Nestin + /Tuj-1 + staining ( Fig. 1G -H) were characteristic of neuronal progenitor cells.
The abilities of proliferation and multipotent differentiation were also assessed in these cultures. In proliferation tests, almost all cells were Ki67 + among which some were BrdU + (Fig. 1J-L) , indicating that obtained cultures possessed the ability of self-renewal. When NSPC cultures were grown in spontaneous differentiation medium for 3 wks, differentiated cells were Tuj-1 + (nascent neurons) or glial fibrillary acidic protein (GFAP + ) (astrocytes), and no overlap of Tuj-1 + and GFAP + staining was observed ( Fig 1M-O) , indicating the cultures had the capacity for multipotent differentiation.
NMDAR subunits were detected in the fetal brain sections and cultured NSPCs. NMDAR 1 was expressed in the entire embryonic brain ( Fig. 2A-C) and in cultured NSPCs (Fig. 2D-E) . Additionally, NMDAR 1 expression in the cortical plate ( Fig. 2A ) was higher than in the ventricular zone and subventricular zone (Fig.  2C ). NMDAR 2B, specific to the developing brain, was expressed in NSPCs ( Fig.  2G ), whereas the expression of NR2A, characteristic of the adult brain, was weak in the fetal cortex (Fig. 2F ). Although expression of the subunits indicates that ketamine may induce some responses in NSPCs, it is unclear whether these subunits are assembled or functional as NMDARs.
NSPCs Are Resistant to Ketamine-Induced Cell Death. In apoptosis assays, we measured activated caspase-3 cells in NSPCs exposed to different ketamine concentrations: 0, 1, 10, 20, 50, and 100 µM for 24 hrs. No significant differences occurred in caspase-3 + cells between the control and ketamine groups (ANOVA, p=.181, n=10), indicating no dosedependent effects of ketamine on apoptosis in NSPCs (Fig.3A) . These results suggest that cultured NSPCs are resistant to ketamine-induced apoptosis at clinically relevant concentrations for 24 hrs (8) .
LDH assays were utilized to detect necrotic changes in ketamine-exposed cultured NSPCs. Although LDH release also occurs at a late stage of apoptosis, this release is insignificant compared to the LDH release from necrosis. Therefore, LDH assays represent the necrotic changes in NSPCs exposed to ketamine. In this study, no tested concentrations of ketamine elevated LDH levels in the culture media (ANOVA, p = .57). In all ketamine groups, LDH release was significantly lower than in the maximal release group (NSPCs treated with Triton X-100) and the LDH positive control (bovine LDH) (ANOVA, p<.0001) (Fig. 3B) . These data suggest that ketamine does not induce cell death in NSPCs.
In time-dependent apoptosis assays (0-48 hrs), no significant changes in apoptosis occurred in cultured NSPCs following exposure to 10-µM ketamine for upto 48 hrs, as compared to control (ANOVA, p = .989) ( Fig. 3C ). All durations of exposure showed low apoptotic rates (<0.3%). In the LDH detection of necrosis, NSPC cultures were exposed to 10 µM of ketamine for different durations (0, 1, 2, 6, 12, 18, 24, and 48 hrs) while parallel controls without ketamine exposure were set up for comparisons at each duration. Paired t tests indicated no significant difference in LDH release between the parallel controls and ketamine treatment groups at each time point (Fig. 3D ). Taken together, these data suggest that ketamine does not time dependently induce cell death in NSPCs.
Ketamine Inhibits the Proliferation of NSPCs. In dose-response assays, we found that the percentage of BrdU + /DAPI + cells in cultured NSPCs exposed to 100 µM of ketamine decreased to 32.3±1.4%, compared to the controls at 41.5±1.6% (ANOVA, p=.0036; Bonferroni, p<.001) (Fig. 4C ). Two typical pictures are shown in Fig. 4B1-B2 . Ketamine at 20, 50, and 100 µM reduced the percentages of Ki67 + / DAPI + cells compared with the control (ANOVA, p < .0001; Bonferroni, p < .001). No significant changes occurred in the percentage of Ki67 + /DAPI + cells at low or clinically relevant concentrations of ketamine (1, 10 µM) ( Fig. 4D ). No significant changes occurred in the percentage of BrdU + /Ki67 + cells compared to the controls at any of the ketamine concentrations used (Fig. 4E) .
In the BrdU-incorporation assays, the number of newly generated cells (BrdU + / DAPI + ) following BrdU exposure for 24 hrs was reduced by approximately 9% at 100 µM ketamine. In Ki67 staining, proliferative cells (Ki67 + /DAPI + ) were also reduced (6.4% for 20-µM, 14.1% for 50-µM, and 15.8% for 100-µM ketamine) compared to the control. These results imply that ketamine inhibits the proliferation of cultured NSPCs in a dose-dependent manner (Fig. 4F ).
In the time-dependent assays, parallel controls were included for each duration of ketamine exposure (Fig. 5A) . Only long-term exposure (48 hrs) to 10 µM of ketamine reduced the percentages of BrdU + /DAPI + (t tests, p < .01) and Ki67 + / DAPI + (t tests, p < .01) cells compared to controls ( Fig. 5B-C) . No significant changes occurred for the percentages of BrdU + /Ki67 + cells at any duration tested (Fig. 5D ). These data indicate that only long-term exposures to a clinically relevant concentration of ketamine can significantly inhibit the proliferation of NSPCs.
Ketamine Enhances the Neuronal Differentiation of NSPCs. Neuronal differentiation of cultured NSPCs exposed to different concentrations of ketamine was detected using Tuj-1 staining. Without ketamine exposure, 34.3±4.1% of control NSPCs differentiated into newborn neurons (Tuj-1 + ). Compared with controls, all tested concentrations of ketamine significantly increased the percentages of Tuj-1 + /DAPI + cells (ANOVA, p < .0001; Bonferroni, p < .05) (Fig. 6C) . Typical Tuj-1 staining images of the 0-, 10-, and 100-µM ketamine groups are presented in Figure 6B , showing increases in Tuj-1 + staining in the 10-and 100-µM groups. In the time-dependent assays, short-term ketamine exposure did not induce any increase of neuronal differentiation in cultured NSPCs, whereas the long-term exposures (≥10 hrs) significantly enhanced differentiation of cultured NSPCs into neurons (ANOVA, p < .0001; Bonferroni, p < .01) (Fig. 7) . These data indicate that ketamine promotes neuronal differentiation of cultured NSPCs in a time-and dosedependent manner.
DISCUSSION
Ketamine sedation and anesthesia are widely used for children and infants, including preterm neonates (27, 28) . Developmental changes occurring at these stages may involve mature neurons and NSPCs. In vivo and in vitro animal studies have reported ketamine-induced . Dose-dependent effects of ketamine on the proliferation of neural stem progenitor cells (NPSCs). A, Ketamine (concentrations: X = 0, 1, 10, 20, 50, or 100 µM) and bromo-deoxyuridine (BrdU) were added to culture media for 24 hrs, then cells were fixed and stained with anti-BrdU and anti-Ki67 antibodies; B, Two typical pictures showing the difference of BrdU and Ki67 staining between the control (B1) and 100 µM ketamine (B2) groups. In the images, green or white points are BrdU + cells; purple points are Ki67 + and BrdU -. (Scale bar = 50 µm.); C-F, Dose-dependent effects of ketamine on the proliferation of NSPCs. C,the percentage of BrdU + cells in total 4′ 6-diamidino-2-phenylindole cells (DAPI + ) is plotted versus different concentrations of ketamine; D, The percentage of Ki67 + cells in the total cells (DAPI + ) exposed to ketamine; E, The percentage of BrdU + cells in Ki67 + cells represents the percentage of proliferating cells to the cells having proliferative capacity; F, A combined graph of graphs C and D. (Stars represent significant differences ketamine vs. control.) neuronal apoptosis in the newborn brain (5, 8, 29) , with specific brain regions being highly vulnerable to NMDAR blockade in early development (3) . Prolonged ketamine anesthesia (24 hrs) in newborn monkeys was also associated with long-term cognitive deficits (30) . However, neurotoxic effects of ketamine exposure in neurons cannot be extrapolated to NSPCs, because the mechanisms regulating cell signaling, survival, and cell death are significantly different between neurons and their progenitors (10, 31, 32) .
In contrast to previous findings, we found that cultured NSPCs were resistant to apoptotic and necrotic cell death across a broad range of concentrations and durations of ketamine exposure. Prolonged exposure (48 hrs) and high concentrations (20, 50, 100 µM) of ketamine significantly inhibited the proliferation of NSPCs. Ketamine exposure also enhanced neuronal differentiation at all concentrations tested for 24 hrs (1-100 µM) and at clinically relevant concentrations (10µM) for ≥10 hrs.
One explanation for the resistance of NSPCs to ketamine-induced cell death (necrosis or apoptosis) may be the lack of functional NMDARs. Glutamate-receptor stimulation does not induce Ca 2+ influx into neural stem cells, suggesting a lack of functional NMDA activity (33) . In neural precursor cells of the postnatal olfactory bulb, increased calcium permeability was mediated by α-amino-3-hydroxy-5methyl-4-isoxazolepropionic acid receptors not NMDA receptors, although high doses of glutamate could induce intracellular calcium currents (34) . Despite the robust expression of NMDAR subunits, functional NMDARs in NSPCs are not expressed until a later stage of neuronal commitment or initiation of synaptic communication (35) (36) (37) . Thus, ketamine exposure may not lead to neurotoxicity in cultured NSPCs possibly due to the absence of functional NMDARs.
The neurogenesis of NSPCs plays a pivotal role in early neural development (38) . Any factor disturbing the precisely controlled and highly regulated cellular events during neurogenesis could result in abnormalities in brain structure and function (39) . Exposing NSPCs to high concentrations of ketamine (20, 50, 100 µM) for 24 hrs, or therapeutic concentrations of ketamine (10 µM) for 48 hrs notably inhibited their proliferation rates. Consistent with our findings, a recent study reported that high-dose S(+) ketamine blocked proliferation in the postischemic rat brain in a dose-dependent manner (40) . Another in vitro study also found that proliferation of NSPCs in cultured neurospheres was grossly inhibited by MK-801, an NMDAR antagonist like ketamine (16) .
The role of NMDARs in hippocampal neurogenesis in the normal or postinjured animal models remains controversial (12, (41) (42) (43) partly because of the different models used. Previous studies focused on neurogenesis in the adult hippocampus, which may present different biological properties from those of cortical fetal NSPCs. Also, those studies used MK-801, which is a more specific NMDAR antagonist than ketamine. Ketamine interacts with many other receptors, such as dopaminergic, serotonergic, and other receptors (44) . Neuronal proliferation in the hippocampus may also be affected by NMDA blockade-induced potential changes in the local microenvironments, including cytokine secretion, activation or deactivation of neurons and astrocytes (45) . NMDAR activation promotes the neuronal differentiation of NPCs (11, 19, 46, 47) , whereas we found that ketamineinduced NMDA blockade also promoted the neuronal differentiation of cultured NSPCs. In our experiments, ketamine may have induced the expression of NMDA-receptor subunits in NSPCs exposed for 24 hrs. Previous studies have also reported that ketamine induces expression of the NMDAR 1 subunit in neurons (8) . As neuronal differentiation proceeds, we posit that ketamine may upregulate the functional NMDARs formed, thus enabling increased calcium influx (37) and promoting the neuronal differentiation of NPSCs (48) . We also found that exposures to 10 µM ketamine for ≥10 hrs resulted in significantly increased neuronal differentiation, thereby potentially creating the conditions for synaptogenesis and NMDAR-mediated calcium influx. Further studies will examine the expression and functional activity of NMDARs in the cultured NSPCs exposed to ketamine.
The consequences of ketamineinduced changes in neurogenesis in the developing brain are speculative. First, since proliferation of NSPCs in the ventricular zone is inhibited, this could reduce the cellularity of the developing brain, leading to a paucity of the neurons/ glia required for normal brain development. Second, earlier differentiation of NSPCs during neuronal migration may result in abnormally positioned neurons within the cortical layers. Last, ketamine exposure in utero could disturb the internal structure of the cortex and the formation of neuronal circuits, possibly leading to altered brain functions. Syndromes associated with the migration arrest of immature neurons are associated with seizures, cognitive deficits, and other clinical features (49, 50) .
A pharmacological model for schizophrenia based on NMDA-receptor hypofunction was noted following acute (51, 52) or chronic (53-55) administration of NMDA-receptor antagonists (phencyclidine, ketamine, and MK-801). As noted in this study, the proliferation of NSPCs is also reduced in schizophrenia (56) . However, the validity of the NMDA hypofunction theory has been questioned as a model for human schizophrenia (51, 57) . For example, ketamine exposure fails to match the cognitive and mood dysfunctions accompanying schizophrenia (57) . Additionally, since schizophrenia tends to not manifest until adolescence it is difficult to assess whether reduced numbers of embryonic or newborn NSPCs would predispose an individual to manifest schizophrenia in the future. We propose in vivo studies to investigate these ketamine-induced changes in neurogenesis and their functional consequences.
Human NSPCs exist throughout the entire life span. However, adult NPCs have different biological characteristics from fetal NSPCs, such as proliferation capacity and differentiation direction. In the adult brain, it is likely more NPCs would differentiate into glia to repair and protect damaged brain regions (58) . Our NSPCs were isolated from the ventricular and subventricular zones of rat fetal cortices. In the adult, NPCs are only located at the subventricular zone, and the ventricular zone is absent after brain development. Therefore, we cannot extrapolate our findings from fetal cortical NSPCs to adult cortical NPCs. These findings imply, however, that ketamine could also affect the neurogenesis of adult NPCs in the post-traumatic brain. Assuming that ketamine leads to similar changes in adult NPCs as with fetal NSPCs, ketamine exposure during neurosurgical anesthesia or other neurological illnesses could potentially damage the repair mechanisms operating in the mature brain.
This study successfully utilized cultured fetal NSPCs as a research tool for Figure 6 . Dose-dependent effects of ketamine on neuronal differentiation of neural stem progenitor cells (NPSCs). A, Dose-dependent effects of ketamine on neuronal differentiation of NSPCs exposed to ketamine (concentration: X = 0, 1, 10, 20, 50, and 100 µM) over a 3-wk spontaneous differentiation phase; B, Tuj-1 staining of differentiated NSPCs exposed to 0, 10, and 100 µM of ketamine for 24 hrs; C, Changes in the percentage of the Tuj-1 + cells in total 4′ 6-diamidino-2-phenylindole cells (DAPI + ) vs. ketamine concentrations. (Stars represent the significant differences ketamine vs. control.) evaluating the developmental neurotoxicity of ketamine. Ketamine does not induce cell death in cultured NSPCs but inhibits the proliferation and enhances the neuronal differentiation of NSPCs in a dose-and time-dependent manner. The developmental neurotoxicity of other anesthetics, sedatives, and analgesics, or various drug combinations can be investigated using a similar approach. Future studies will be conducted to confirm these findings using in vivo rodent or nonhuman primate models, and even cultured human NSPCs, and to investigate the underlying cellular mechanisms.
